118 related articles for article (PubMed ID: 30320629)
1. A plasma microRNA biomarker of melanoma as a personalised assessment of treatment response.
van Laar RK; Lincoln MT; van Laar BJ
Melanoma Res; 2019 Feb; 29(1):19-22. PubMed ID: 30320629
[TBL] [Abstract][Full Text] [Related]
2. Translation of a circulating miRNA signature of melanoma into a solid tissue assay to improve diagnostic accuracy and precision.
Laar RV; King S; McCoy R; Saad M; Fereday S; Winship I; Uzzell C; Landgren A
Biomark Med; 2021 Sep; 15(13):1111-1122. PubMed ID: 34184547
[No Abstract] [Full Text] [Related]
3. Identification of a Circulating MicroRNA Profile as a Biomarker of Metastatic Cutaneous Melanoma.
Armand-Labit V; Meyer N; Casanova A; Bonnabau H; Platzer V; Tournier E; Sansas B; Verdun S; Thouvenot B; Hilselberger B; Doncescu A; Lamant L; Lacroix-Triki M; Favre G; Pradines A
Acta Derm Venereol; 2016 Jan; 96(1):29-34. PubMed ID: 26039581
[TBL] [Abstract][Full Text] [Related]
4. Validation of a microRNA liquid biopsy assay for diagnosis and risk stratification of invasive cutaneous melanoma.
Van Laar R; Latif B; King S; Love C; Taubenheim N; Kalansooriya E; Wang W; Saad M; Winship I; Azzi A; Lilleyman A; Landgren T
Br J Dermatol; 2023 Aug; 189(3):292-301. PubMed ID: 37144735
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a plasma-based melanoma biomarker suitable for clinical use.
Van Laar R; Lincoln M; Van Laar B
Br J Cancer; 2018 Mar; 118(6):857-866. PubMed ID: 29360813
[TBL] [Abstract][Full Text] [Related]
6. Sensitive detection of melanoma metastasis using circulating microRNA expression profiles.
Shiiyama R; Fukushima S; Jinnin M; Yamashita J; Miyashita A; Nakahara S; Kogi A; Aoi J; Masuguchi S; Inoue Y; Ihn H
Melanoma Res; 2013 Oct; 23(5):366-72. PubMed ID: 23863473
[TBL] [Abstract][Full Text] [Related]
7. Characterisation and validation of Mel38; A multi-tissue microRNA signature of cutaneous melanoma.
Van Laar R; Lincoln M; Fereday S
PLoS One; 2019; 14(2):e0211504. PubMed ID: 30721246
[TBL] [Abstract][Full Text] [Related]
8. Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma.
Fogli S; Polini B; Carpi S; Pardini B; Naccarati A; Dubbini N; Lanza M; Breschi MC; Romanini A; Nieri P
Tumour Biol; 2017 May; 39(5):1010428317701646. PubMed ID: 28466785
[TBL] [Abstract][Full Text] [Related]
9. MicroRNAs in cutaneous melanoma: Role as diagnostic and prognostic biomarkers.
Ross CL; Kaushik S; Valdes-Rodriguez R; Anvekar R
J Cell Physiol; 2018 Jul; 233(7):5133-5141. PubMed ID: 29226953
[TBL] [Abstract][Full Text] [Related]
10. Decreased serum microRNA-206 level predicts unfavorable prognosis in patients with melanoma.
Tian R; Liu T; Qiao L; Gao M; Li J
Int J Clin Exp Pathol; 2015; 8(3):3097-103. PubMed ID: 26045823
[TBL] [Abstract][Full Text] [Related]
11. Plasma microRNA-21 is associated with tumor burden in cutaneous melanoma.
Saldanha G; Potter L; Shendge P; Osborne J; Nicholson S; Yii N; Varma S; Aslam MI; Elshaw S; Papadogeorgakis E; Pringle JH
J Invest Dermatol; 2013 May; 133(5):1381-4. PubMed ID: 23303460
[No Abstract] [Full Text] [Related]
12. Malignant melanoma--markers for progression and prognosis in malignant melanoma.
Geilen CC; Georgieva J; Milling A; Farthmann B
Front Radiat Ther Oncol; 2006; 39():120-126. PubMed ID: 16394675
[No Abstract] [Full Text] [Related]
13. A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients.
Ono S; Oyama T; Lam S; Chong K; Foshag LJ; Hoon DS
Oncotarget; 2015 Mar; 6(9):7053-64. PubMed ID: 25749524
[TBL] [Abstract][Full Text] [Related]
14. Tumor biomarkers in melanoma.
Ugurel S; Utikal J; Becker JC
Cancer Control; 2009 Jul; 16(3):219-24. PubMed ID: 19556961
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of chromosomal aberrations and epigenetic changes in peripheral blood samples to identify patients with melanoma.
Jakub JW; Grotz TE; Jordan P; Hunter E; Pittelkow M; Ramadass A; Akoulitchev A; Markovic S
Melanoma Res; 2015 Oct; 25(5):406-11. PubMed ID: 26225582
[TBL] [Abstract][Full Text] [Related]
16. Serum microRNAs as biomarkers for recurrence in melanoma.
Friedman EB; Shang S; de Miera EV; Fog JU; Teilum MW; Ma MW; Berman RS; Shapiro RL; Pavlick AC; Hernando E; Baker A; Shao Y; Osman I
J Transl Med; 2012 Aug; 10():155. PubMed ID: 22857597
[TBL] [Abstract][Full Text] [Related]
17. Circulating biomarkers in malignant melanoma.
Alegre E; Sammamed M; Fernández-Landázuri S; Zubiri L; González Á
Adv Clin Chem; 2015; 69():47-89. PubMed ID: 25934359
[TBL] [Abstract][Full Text] [Related]
18. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker.
Kanemaru H; Fukushima S; Yamashita J; Honda N; Oyama R; Kakimoto A; Masuguchi S; Ishihara T; Inoue Y; Jinnin M; Ihn H
J Dermatol Sci; 2011 Mar; 61(3):187-93. PubMed ID: 21273047
[TBL] [Abstract][Full Text] [Related]
19. Serum miR-16: A Potential Biomarker for Predicting Melanoma Prognosis.
Guo S; Guo W; Li S; Dai W; Zhang N; Zhao T; Wang H; Ma J; Yi X; Ge R; Wang G; Gao T; Li C
J Invest Dermatol; 2016 May; 136(5):985-993. PubMed ID: 26829037
[TBL] [Abstract][Full Text] [Related]
20. Circulating cell-free microRNAs in cutaneous melanoma staging and recurrence or survival prognosis.
Polini B; Carpi S; Romanini A; Breschi MC; Nieri P; Podestà A
Pigment Cell Melanoma Res; 2019 Jul; 32(4):486-499. PubMed ID: 30481404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
